Citations

Clear

3485 citation(s) found for "Sy, Sarah".

The SERPINA5 coding variant E228Q does not contribute to clinicopathologic characteristics in Alzheimer’s disease: A cross-sectional study
Lincoln, Sarah, Baker, Matt , Tamvaka, Nikoleta, Sirmans, Tiffany N. Hicks , Moloney, Christina M. , Helminger, Jacqueline, Hinkle, Kelly M., Cabrera-Rodriguez, Janisse, Wickland, Daniel P. , Reddy, Joseph S. , Younkin, Steven G. , Carrasquillo, Minerva M. , Duara, Ranjan , Graff‐Radford, Neill R. , Pottier, Cyril , Ertekin‐Taner, Nilüfer , Ross, Owen A. , Rademakers, Rosa , Matchett, Billie J. , Lincoln, Sarah J, Labuzan, Sydney A. , Hicks Sirmans, Tiffany N, Murray, Melissa E , Ross, Owen A , Pottier, Cyril , Johnson, Patrick W. , Heckman, Michael G. , Carrasquillo, Minerva M. , Duara, Ranjan , Dickson, Dennis W. , Murray, Melissa E.

Mayo Clinic

Medicine | June 16, 2023 | Volume: 102 | Issue: 24 | Pages: e34017

10.1097/md.0000000000034017 | PMID 37327267 Get It

We previously demonstrated that increased expression of the SERPINA5 gene is associated with hippocampal vulnerability in Alzheimer’s disease (AD) brains. SERPINA5 was further demonstrated to be a novel tau-binding partner that colocalizes within neurofibrillary tangles. Our goal was to determine whether genetic variants in the SERPINA5 gene contributed to clinicopathologic phenotypes in AD. To screen for SERPINA5 variants, we sequenced 103 autopsy-confirmed young-onset AD cases with a positive family history of cognitive decline. To further assess the frequency of a rare missense variant, SERPINA5 p.E228Q, we screened an additional 1114 neuropathologically diagnosed AD cases. To provide neuropathologic context in AD, we immunohistochemically evaluated SERPINA5 and tau in a SERPINA5 p.E228Q variant carrier and a matched noncarrier. In the initial SERPINA5 screen, we observed 1 individual with a rare missense variant (rs140138746) that resulted in an amino acid change (p.E228Q). In our AD validation cohort, we identified an additional 5 carriers of this variant, resulting in an allelic frequency of 0.0021. There was no significant difference between SERPINA5 p.E228Q carriers and noncarriers in terms of demographic or clinicopathologic characteristics. Although not significant, on average SERPINA5 p.E228Q carriers were 5 years younger at age of disease onset than noncarriers (median: 66 [60–73] vs 71 [63–77] years, P = .351). In addition, SERPINA5 p.E228Q carriers exhibited a longer disease duration than noncarriers that approached significance (median: 12 [10–15]) vs 9 [6–12] years, P = .079). More severe neuronal loss was observed in the locus coeruleus, hippocampus, and amygdala of the SERPINA5 p.E228Q carrier compared to noncarrier, although no significant difference in SERPINA5-immunopositive lesions was observed. Throughout the AD brain in either carrier or noncarrier, areas with early pretangle pathology or burnt-out ghost tangle accumulation did not reveal SERPINA5-immunopositive neurons. Mature tangles and newly formed ghost tangles appeared to correspond well with SERPINA5-immunopositive tangle-bearing neurons. SERPINA5 gene expression was previously associated with disease phenotype; however, our findings suggest that SERPINA5 genetic variants may not be a contributing factor to clinicopathologic differences in AD. SERPINA5-immunopositive neurons appear to undergo a pathologic process that corresponded with specific levels of tangle maturity.
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
Fa’ak, Faisal , Buni, Maryam, Falohun, Adewunmi, Song, Juhee , Trinh, Van Anh, Tahon, Nourel Hoda , Elsayes, Khaled M. , Ludford, Kaysia , Montazari, Emma J., Chernis, Julia , Dimitrova, Maya , Sandigursky, Sabina, Sparks, Jeffrey A. , Abu-Shawer, Osama , Rahma, Osama E. , Thanarajasingam, Uma , Zeman, Ashley M., Talukder, Rafee , Chung, Sarah H. , Grivas, Petros , Daher, May , Abudayyeh, Ala , Osman, Iman , Suarez‐Almazor, María E. , Abdel‐Wahab, Noha , Diab, Adi , Grivas, Petros , Weber, Jeffrey , Diab, Adi , Sparks, Jeffrey A , Lu, Huifang , Johnson, Daniel Hartman , Zobniw, Chrystia M. , Awiwi, Muhammad O. , Singh, Namrata , Weber, Jeffrey S. , Tayar, Jean H.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | June 16, 2023 | Volume: 11 | Issue: 6 | Pages: e006814

10.1136/jitc-2023-006814 | PMID 37328287 Get It

Background Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the safety and effectiveness of anti-interleukin-6 receptor (anti-IL-6R) as therapy for irAEs. Methods We performed a retrospective multicenter study evaluating patients diagnosed with de novo irAEs or flare of pre-existing autoimmune disease following ICI and were treated with anti-IL-6R. Our objectives were to assess the improvement of irAEs as well as the overall tumor response rate (ORR) before and after anti-IL-6R treatment. Results We identified a total of 92 patients who received therapeutic anti-IL-6R antibodies (tocilizumab or sarilumab). Median age was 61 years, 63% were men, 69% received anti-programmed cell death protein-1 (PD-1) antibodies alone, and 26% patients were treated with the combination of anti-cytotoxic T lymphocyte antigen-4 and anti-PD-1 antibodies. Cancer types were primarily melanoma (46%), genitourinary cancer (35%), and lung cancer (8%). Indications for using anti-IL-6R antibodies included inflammatory arthritis (73%), hepatitis/cholangitis (7%), myositis/myocarditis/myasthenia gravis (5%), polymyalgia rheumatica (4%), and one patient each with autoimmune scleroderma, nephritis, colitis, pneumonitis and central nervous system vasculitis. Notably, 88% of patients had received corticosteroids, and 36% received other disease-modifying antirheumatic drugs (DMARDs) as first-line therapies, but without adequate improvement. After initiation of anti-IL-6R (as first-line or post-corticosteroids and DMARDs), 73% of patients showed resolution or change to ≤grade 1 of irAEs after a median of 2.0 months from initiation of anti-IL-6R therapy. Six patients (7%) stopped anti-IL-6R due to adverse events. Of 70 evaluable patients by RECIST (Response Evaluation Criteria in Solid Tumors) V.1.1 criteria; the ORR was 66% prior versus 66% after anti-IL-6R (95% CI, 54% to 77%), with 8% higher complete response rate. Of 34 evaluable patients with melanoma, the ORR was 56% prior and increased to 68% after anti-IL-6R (p=0.04). Conclusion Targeting IL-6R could be an effective approach to treat several irAE types without hindering antitumor immunity. This study supports ongoing clinical trials evaluating the safety and efficacy of tocilizumab (anti-IL-6R antibody) in combination with ICIs ( NCT04940299 , NCT03999749 ).
Medical School Curricula: Giving Radiation Oncology a Seat at the Table
Chaurasia, Avinash , Price, Jeremy , Jeans, Elizabeth B. , Dooley, Sarah A.

Mayo Clinic

Applied Radiation Oncology | June 16, 2023 | Volume: No volume available | Issue: No issue available | Pages: 4-4

10.37549/aro1278 Get It

Personalizing Approaches to Patient Education Throughout the Radiation Oncology Workflow
Goldman, J.W., Londoño, Valeria, Hoffe, Sarah E. , Goldman, Jodi, Lin, Keldon K.

Mayo Clinic

Applied Radiation Oncology | June 16, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.37549/aro1331 Get It

Transcriptome profiling in AD cases to identify distinct associations with AD‐related neuropathology and protein levels in the brain
Allen, Mariet , Quicksall, Zachary , Wang, Xue , Reddy, Joseph S. , Bergman, Jeremiah, Oatman, Stephanie R., Nguyen, Thuy , Malphrus, Kimberly G., Lincoln, Sarah, Martens, Yuka A. , DeTure, Michael , Kanekiyo, Takahisa , Ertekin‐Taner, Nilüfer , Yamazaki, Yu , Zhao, Na , Murray, Melissa E. , Liu, Chia‐Chen , Dickson, Dennis W. , Bu, Guojun

Mayo Clinic

Alzheimer's & Dementia | June 16, 2023 | Volume: 19 | Issue: S1 | Pages: No page available

10.1002/alz.067201 Get It

AbstractBackgroundGene expression changes have been identified in post‐mortem brain tissue of AD cases when compared with controls, implicating various genes and pathways. Such findings provide important insights into molecular dysregulation associated with this disease and nominate therapeutic targets. Here we investigate brain gene and co‐expression network changes in a cohort of AD cases to identify associations with degree of AD neuropathology including Braak stage (Tau), Thal phase (Amyloid beta) and brain tissue levels of five AD‐related proteins (apoE, Aβ40, Aβ42, tau, and p‐tau).MethodGene expression measures were collected from temporal cortex (TCX) tissue of 477 AD cases, available through the Mayo Clinic Brain Bank, using RNA sequencing (Illumina TruSeq mRNA) performed on the HiSeq4000. Following quality control 456 cases remained for analysis. Braak and Thal were provided by an experienced neuropathologist and TCX levels of five AD‐related proteins from three fractions (buffer‐soluble, detergent‐soluble, and insoluble) were measured by ELISA (Liu et al. 2020). Weighted gene coexpression network analysis (WGCNA) R package was used to build co‐expression networks. Genes and networks were tested for association with neuropathology and AD‐related protein levels, adjusting for relevant covariates.ResultA total of 57,353 genes were profiled, of which 19,044 were reliably expressed above background levels and formed 20 co‐expression modules. 36 genes were associated with Braak stage, 10 with Thal phase and up to 9,000 with the AD‐related protein fractions. Brain levels of pTau had the greatest number of associations, with an overrepresentation of genes involved in synaptic signalling and immune response gene ontology biological processes. 16 of the coexpression modules associated with at least one trait after Bonferroni correction for number of tests.ConclusionWe have identified a number of genes and networks associated with different aspects of AD neuropathology and associated proteins, further lending support to the involvement of synaptic and immune biology in AD. However it is not clear whether observed changes cause disease or are a consequence of the neurodegenerative process. Comparison of these findings across different proteins and fractions is expected to reveal common and distinct vulnerabilities associated with amyloid and tau, and different stages of protein aggregation.
Abstract 9623: Shared Decision Making for Atrial Fibrillation: An Overview of Seven Studies Within an Encounter - Randomized Trial
Kunneman, Marleen , Hargraves, Ian , Sivly, Angela , Gorr, Haeshik, Burnett, Bruce , Investigators, Shared Decision Making for Atrial Fibrillation (SDM4AFib) Trial, Branda, Megan E. , Lee, Alexander , Burnett, Bruce, Suzuki, Takeki , Jackson, Elizabeth A. , Hess, Erik P. , Linzer, Mark , McCarthy, Sarah , Kamath, Celia , Brito, Juan P. , Noseworthy, Peter A. , Montori, Víctor M. , Investigators, Shared Decision Making for Atrial Fibrillation (SDM4AFib) Trial

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.9623 Get It

Introduction: Shared decision-making (SDM) about anticoagulant treatment in patients with atrial fibrillation (AF) is widely recommended but its effectiveness is unclear. We assessed the extent to which using an SDM tool promotes high-quality SDM. Hypothesis: SDM will improve communication quality, knowledge, and decisional conflict and will translate to improved medication adherence and outcomes. Methods: In this multicentre encounter-randomized trial, we included patients with nonvalvular AF considering starting/reviewing anticoagulation, and their clinicians. We compared usual care with or without ANTICOAGULATION CHOICE, an SDM conversation tool for use during the clinical encounter that presents individualized risk estimates and compares anticoagulation options across patient important issues. Results: We enrolled and video-recorded 922 patient-clinician encounters. So far, our data have shown that participants in both arms reported near-optimal communication quality, knowledge, and decisional conflict (JAMA IM-2020). Patients in intervention-arm estimated their stroke risks more accurately and were more involved in decision-making (JAMA IM-2020), clinicians were more satisfied (JAMA IM-2020), and cost conversation were more common (JAMA NO-2021). Use of the intervention had no effect on treatment decisions, encounter duration (JAMA IM-2020), treatment adherence, clinical outcomes (JAHA-epub) or patient-perceived sense of the care plan (PEC-epub). New analyses have shown that compared to eligible white participants, black participants more frequently did not enrol to the study. Enrolment of Black, indigenous, and people of colour benefited most form including and prioritizing practices most likely to care for them. We found no evidence of contamination (tool use, functional, or learned) between study arms. Conclusions: Use of an SDM tool improved some measures of SDM quality, without affecting treatment decisions and their sensibility, encounter duration, patient adherence, or clinical outcomes. Our results should calibrate expectations as to what could be accomplished by implementing SDM tools about anticoagulation in the care of patients with AF
Abstract 13915: Man vs. Machine: A Direct Comparison of the Diagnostic Efficacy of Novel Automated WCT Differentiation to Traditional Manual ECG Interpretation Approaches
LoCoco, Sarah , Kashou, Anthony H. , Deshmukh, Abhishek , Cooper, Daniel , Cuculich, Phillip S. , Sodhi, Sandeep , Asirvatham, Samuel J. , Noseworthy, Peter A. , DeSimone, Christopher V. , May, Adam M.

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.13915 Get It

BACKGROUND: Differentiation of wide QRS complex tachycardias (WCTs) into ventricular tachycardia (VT) and supraventricular wide QRS tachycardia (SWCT) through 12-lead electrocardiogram (ECG) interpretation is one of the most critical yet challenging tasks in clinical practice. Recent research highlights novel automated methods that successfully diagnose WCTs. We sought to directly compare the diagnostic efficacy of these novel automated WCT differentiation methods (i.e., WCT Formula, VT Prediction Model, and WCT Formula II) to traditional ECG interpretation approaches (i.e., Brugada and Vereckei aVR algorithms). METHODS: A collection of paired WCT and baselined ECGs were retrospectively analyzed. Next, an electrophysiologist blindly and prospectively applied the Brugada and Vereckei aVR algorithms. Separately, computerized measurements were used to apply the three automated WCT differentiation methods. The diagnostic performance of each method was then evaluated. RESULTS: 213 WCTs (111 VT and 102 SWCT) from 105 patients were analyzed. The WCT Formula demonstrated superior overall accuracy (84.7% vs. 64.8%), specificity (86.2% vs. 35.3%), positive predictive value (PPV) (85.7% vs. 60.7%), and positive (+) likelihood ratio (LR) (6.06 vs. 1.42) compared to Vereckei aVR algorithm. Similarly, the WCT Formula attained higher specificity (86.2% vs. 61.8%), PPV (85.7% vs. 71.9%), and (+) LR (6.06 vs. 2.36) than the Brugada algorithm. The WCT Formula II demonstrated superior overall accuracy (89.2% vs. 64.8%), specificity (84.3 % vs. 35.3%), PPV (86.7% vs. 60.7%), and positive (+) LR (5.97 vs.1.42) compared to Vereckei aVR algorithm as well as higher specificity (84.3 % vs. 61.8 %), PPV (86.7% vs. 71.9%), and (+) LR (5.97 vs. 2.36) than the Brugada algorithm. The VT prediction model yielded superior specificity (79.4% vs. 35.3%), PPV (79.8 vs. 60.7%) and (+) LR (3.63 vs.1.42) compared to the Vereckei aVR algorithm but did not demonstrate superior diagnostic performance to the Brugada algorithm. CONCLUSIONS: Novel automated WCT differentiation methods achieved similar or superior diagnostic performance metrics compared to traditional ECG interpretation approaches.
Hidden Perioperative Risk for Contraceptive Failure
Whitney, Madeline , Dodd, Sarah E. , Whitney, Madeline A, Kraus, Molly B. , Harbell, Monica W.

Mayo Clinic

Journal of Women's Health | June 13, 2023 | Volume: 32 | Issue: 11 | Pages: 1158-1160

10.1089/jwh.2023.0122 | PMID 37311197 Get It

Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Benson, Al B. , Al-Hawary, Mahmoud M. , Azad, Nilofer, Chen, Yi‐Jen , Cooper, Harry S. , Deming, Dustin A. , Garrido‐Laguna, Ignacio , Grem, Jean L. , Hecht, J. Randolph, Hoffe, Sarah E. , Hunt, Steven R., Johung, Kimberly L. , Joseph, Nora, Kirilcuk, Natalie, Krishnamurthi, Smitha , Maratt, Jennifer K. , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Mulcahy, Mary F. , Nurkin, Steven, Overman, Michael J. , Patel, Hitendra , Shibata, David , Skibber, John M., Sofocleous, Constantinos T. , Stotsky‐Himelfarb, Eden, Tavakkoli, Anna , Willett, Christopher G. , Algieri, Frankie, Gurski, Lisa A., Stehman, Katie, Meyerhardt, Jeffrey A , Venook, Alan P. , Ciombor, Kristen K. , Cohen, Stacey A. , Hubbard, Joleen M. , Hussan, Hisham , Jeck, William R. , Miller, Eric D. , Parikh, Aparna R. , Patel, Hitendra, Pedersen, Katrina S. , Saltz, Leonard B. , Schneider, Charles John , Williams, Grant R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 12, 2023 | Volume: 21 | Issue: 6 | Pages: 653-677

10.6004/jnccn.2023.0030 | PMID 37308125 Get It

This discussion summarizes the NCCN Clinical Practice Guidelines for managing squamous cell anal carcinoma, which represents the most common histologic form of the disease. A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is necessary. Primary treatment of perianal cancer and anal canal cancer are similar and include chemoradiation in most cases. Follow-up clinical evaluations are recommended for all patients with anal carcinoma because additional curative-intent treatment is possible. Biopsy-proven evidence of locally recurrent or persistent disease after primary treatment may require surgical treatment. Systemic therapy is generally recommended for extrapelvic metastatic disease. Recent updates to the NCCN Guidelines for Anal Carcinoma include staging classification updates based on the 9th edition of the AJCC Staging System and updates to the systemic therapy recommendations based on new data that better define optimal treatment of patients with metastatic anal carcinoma.
THE PROGNOSTIC IMPACT OF CLINICAL FACTORS AND IMMUNOARCHITECTURAL PATTERNS FOR NODULAR LYMPHOCYTE‐PREDOMINANT HODGKIN LYMPHOMA: AN INTERNATIONAL STUDY BY GLOW
Binkley, Michael S., Borchmann, Peter , Fuchs, Michael , Hartmann, Sylvia , Eich, Hans Theodor, Skinnider, Brian, Steiner, Raphaël , Milgrom, Sarah A. , Alomari, Mohammed H., Zhang, Xieyi , Advani, Ranjana H. , Metzger, Monika L. , Wirth, A., Smith, Sonali M. , Hendrickson, P., Hopkins, David , Ng, Andrea K. , Koenig, Julie L. , Sakthivel, GD, Roberts, Kenneth B. , Gao, Sarah , Kendi, J. Al, Rahbi, Nasser Al, Balogh, Alex, Torka, Pallawi , Silva, Ravi De , Shah, Nimish , Osborne, Wendy , Henry, M M , Chang, Ilsung , Miall, Fiona , Brady, J.L. , Mikhaeel, G., Brennan, Barbara J. , Penn, Andrew M. , Сенченко, М. А. , Reeves, Mark E. , Terezakis, Stephanie , Fergusson, Pamela, Kelly, Kara M. , Advani, Ranjana H , Hopkins, David , Senchenko, Maria Anatolevna , Binkley, Michael S. , Flerlage, Jamie E. , Savage, Kerry J. , Hodgson, David C. , Akhtar, Saad , Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Vega, Francisco , Alomari, M., Zhang, X., Collins, Graham P. , Dickinson, Michael , Tsang, Richard , Prica, Anca A. , Major, Ajay , Kelsey, Chris R. , McKay, Pamela , Constine, Louis S , Casulo, Carla , Baron, J., Plastaras, John Peter , Kendi, J. Al, Levis, Mario , Ricardi, Umberto , Sridhar, A., Specht, Lena , Pickard, Keir , Blazin, Lindsay , Henry, M., Chang, I., Smith, Christine M , Halperin, Daniel M. , Brennan, B., Penn, A., Volchkov, Egor Vasilevich , Reeves, M., Hoppe, Bradford S. , Talaulikar, Dipti , Pepa, Roberta Della , Picardi, Marco , Kirova, Youlia , Fergusson, P., Northend, Michael , Shankar, Ananth , Maurer, Matthew J. , Natkunam, Yasodha , Eichenauer, Dennis A. , Hoppe, Richard T.

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 100-101

10.1002/hon.3163_62 Get It